Publikationen in Zusammenarbeit mit Forschern von Hospital Clinico Universitario de Valencia (10)

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

2016

  1. SEOM Clinical Guideline in ovarian cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1206-1212

2010

  1. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer

    Anticancer Research, Vol. 30, Núm. 6, pp. 2255-2261

2006

  1. Phase II trial of doxorubicin plus escalated high-dose ifosfamide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Sarcoma, Vol. 2006

2005

  1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755

2003

  1. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

    Annals of Oncology, Vol. 14, Núm. 8, pp. 1246-1252

2000

  1. Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy

    Cancer, Vol. 89, Núm. 11, pp. 2169-2175

1997

  1. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: A phase II trial of the Spanish group for ovarian cancer

    Seminars in Oncology

1994

  1. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

    Annals of Oncology, Vol. 5, Núm. 9, pp. 854-857